Amelioration of doxorubicin-induced cardiotoxicity by resveratrol

Molecular Medicine Reports

Volumn 10, Issue 3, 2014, Pages 1455-1460

  Al Harthi, Sameer E ^a   Alarabi, Ohoud M ^a   Ramadan, Wafaa S ^a   Alaama, Mohamed N ^a   Al Kreathy, Huda M ^a   Damanhouri, Zoheir A ^a   Khan, Lateef M ^a   Osman, Abdel Moneim M ^a  

^a Aziz University   (Saudi Arabia)

Author keywords

Cardioprotection; Doxorubicin; Resveratrol

Indexed keywords

CREATINE KINASE; DOXORUBICIN; FREE RADICAL; GLUTATHIONE; LACTATE DEHYDROGENASE; MALONALDEHYDE; RESVERATROL; ANTIOXIDANT; PLANT EXTRACT; POLYPHENOL; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; ELECTRON MICROSCOPY; ENZYME ACTIVITY; EXPERIMENTAL CARDIOVASCULAR DISEASE; HEART PROTECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; NONHUMAN; RAT; ANIMAL; BLOOD; DRUG EFFECTS; HEART; HEART MUSCLE CELL; METABOLISM; OXIDATIVE STRESS; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; CARDIOTOXICITY; CREATINE KINASE; DOXORUBICIN; GLUTATHIONE; HEART; L-LACTATE DEHYDROGENASE; MALE; MALONDIALDEHYDE; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PLANT EXTRACTS; POLYPHENOLS; RATS; RATS, WISTAR; STILBENES;

EID: 84905453918     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2384     Document Type: Article

References (27)

1. Lefrak EA, Pitha J, Rosenheim S and Gofottiebm JA: A clinicopathological analysis of adriamycin cardiotoxicity. Cancer 32: 302-314, 1973.
2. Singal PK and Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 339: 900-905, 1998. (Pubitemid 28446849)
3. Doroshow JH: Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 43: 460-472, 1983.
4. Powis G: Free radical formation by antitumor quinones. Free Radic Biol Med 6: 63-101, 1989.
5. Olson RD and Mushlin PS: Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 4: 3076-3086, 1990.
6. Ogura R, Sugiyama M, Haramaki N and Hidaka T: Electron spin resonance studies on the mechanism of adriamycin-induced heart mitochondrial damages. Cancer Res 51: 3555-3558, 1991.
7. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K and Young RC: Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197: 165-167, 1977. (Pubitemid 8140036)
8. Mimnaugh EG, Trush MA, Bhatnagar M and Gram TE: Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug adriamycin. Biochem Pharmacol 34: 847-856, 1985. (Pubitemid 15107179)
9. Singal PK, Deally CM and Weinberg LE: Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol 19: 817-828, 1987. (Pubitemid 17144746)
10. Goswami SK and Das DK: Resveratrol and chemoprevention. Cancer Lett 284: 1-6, 2009.
11. Alkreathy H, Damanhouri ZA, Ahmed N, Slevin M, Ali SS and Osman AM: Aged garlic extract protects against doxorubicin-induced cardiotoxicity in rats. Food Chem Toxicol 48: 951-956, 2010.
12. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V and Milner A: A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci (Lond) 84: 407-412, 1993. (Pubitemid 23113948)
13. Sugioka K and Nakano M: Mechanism of phospholipid peroxidation induced by ferric ion-ADP-adriamycin-coordination complex. Biochim Biophys Acta 713: 333-343, 1982. (Pubitemid 13222949)
14. Sparano JA: Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations. Semin Oncol 25 (Suppl 10): 66-71, 1998.
15. Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rey M, Sanger J, Kramer E, Ferrans V, Hochster H, Meyers M, et al: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10: 117-127, 1992.
16. Li H, Xia N and Förstermann U: Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide 26: 102-110, 2012.
17. Danz ED, Skramsted J, Henry N, Bennett JA and Keller RS: Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic Biol Med 46: 1589-1597, 2009.
18. Tatlidede E, Sehirli O, Velioǧlu-Oǧünc A, Cetinel S, Yeǧen BC, Yarat A, Süleymanoǧlu S and Sener G: Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radic Res 43: 195-205, 2009.
19. Preus M, Bhargava AS, Khater AE and Günzel P: Diagnostic value of serum creatine kinase and lactate dehydrogenase isoenzyme determinations for monitoring early cardiac damage in rats. Toxicol Lett 42: 225-233, 1988.
20. Osman AM, Al-Shabanah OA and Al-Harbi MM: Effect of desferrioxamine on doxorubicin-induced cardiotoxicity and haematotoxicity in mice. Med Sci Res 21: 193-194, 1993. (Pubitemid 23085487)
21. Hemnani T and Parihar MS: Reactive oxygen species and oxidative DNA damage. Indian J Physiol Pharmacol 42: 440-452, 1998. (Pubitemid 28557746)
22. Van Vleet JF, Ferrans VJ and Weirich WE: Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am J Pathol 99: 13-42, 1980.
23. Nagi MN and Mansour MA: Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: a possible mechanism of protection. Pharmacol Res 41: 283-289, 2000. (Pubitemid 30663132)
24. Al-Majed AA, Gado AM, Al-Shabanah OA and Mansour MA: Alpha-lipoic acid ameliorates myocardial toxicity induced by doxorubicin. Pharmacol Res 46: 499-503, 2002. (Pubitemid 35435691)
25. Osman AM, Al-Harthi SE, Alarabi OM, Elshal MF, Ramadan WS, Alaama MN, Al-Kreathy HM, Damanhouri ZA and Osman OH: Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin-treated animals. Cancer Cell Int 13: 52, 2013.
26. 2+ binding and lipid peroxidation but depresses myocardial function. Am J Physiol 250: H419-H425, 1986.
27. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N and Sawyer DB: Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 26: 3777-3784, 2008.